Yes, we should assume the FDA will require some clinical trials for FoB's—i.e. knockoff drugs where the original brand was approved via a BLA rather than an NDA.
Or should we assume at least some degree of trials...
Management has stated for quite a while that for the initial substitutible generics of biologics the FDA would likely require at least a minimal set of trials.
Market Data 
Markets 
AI
